Drug Trial Radar · NCT00081744
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
Last checked: Nov 19, 2026Latest source record: Feb 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
850
Actual
Start
Nov 2002
Primary completion
Aug 2004
Study completion Aug 2004
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 21, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
Conditions
- Gram-Positive Bacterial Infections
- Cross Infection
Interventions
TigecyclineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.